ANI Pharmaceuticals converted 20,000 Series A Convertible Preferred Shares into 482,320 Common Shares on September 26, 2025, completing the conversion of all preferred shares previously issued, totaling 602,900 Common Shares resulting from this transaction. The initial investment was $25 million, and dividends were set at 6.50% per year.